FDA Approves Portrazza For Metastatic Lung Cancer

Tuesday, December 1st, 2015

The FDA has given approval to Portrazza to be used along with two chemotherapy treatments for the treatment of those patients suffering from metastatic squamous NSCLC (non-small cell lung cancer) who previously have not been prescribed medication specifically for the treatment of their metastatic lung cancer. This drug’s efficacy and safety were evaluated through a […]